Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus

To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ketaren, Natalia E., Mast, Fred D., Fridy, Peter C., Paul Olivier, Jean, Sanyal, Tanmoy, Sali, Andrej, Chait, Brian T., Rout, Michael P., Aitchison, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369967/
https://www.ncbi.nlm.nih.gov/pubmed/37503298
http://dx.doi.org/10.1101/2023.07.14.549041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369967/
https://www.ncbi.nlm.nih.gov/pubmed/37503298
http://dx.doi.org/10.1101/2023.07.14.549041

Ejemplares similares